PTPRC and neoplasm: Flow cytometry analyses showed that the proportion of intra-tumor CD3+ (Fig. 1k, l), CD4+ (Fig. 1m), and CD8+ T cells (Fig. 1n) in CD45+ cells was lower in uIRI-Can than in Sham-Can.